Dermapharm Holding SE Meets Q1 2025 Expectations, Reinforces Full-Year Forecast

Dermapharm Holding SE reported positive results for Q1 2025, aligning with expectations and reaffirming its full-year financial guidance. The company saw a 1.2% increase in consolidated revenue, reaching EUR 302.4 million. Despite an 8.3% decline in adjusted EBITDA, which fell to EUR 81.3 million due to non-recurring previous year items, the company maintained a solid performance driven by its "Branded pharmaceuticals" segment.

The "Branded pharmaceuticals" segment exhibited a 1.9% revenue increase, reaching EUR 145.7 million, emphasizing international growth and allergy therapeutics. Conversely, the "Other healthcare products" segment faced a slight decline, generating EUR 96.2 million. However, the "Parallel import business" segment experienced a 7.1% rise, contributing to the overall revenue progression. Dermapharm remains confident about reaching its annual goals of a EUR 1,160–1,200 million revenue and adjusted EBITDA of EUR 322–332 million despite these mixed results.